Mycosis Fungoides

Stage IB-IIA

Skin Directed Therapy

Any Body Surface Area (BSA)

10% BSA

LYMNHL0143 Phase II CD11301 0.03% & 0.06% Gel in Tx of Cutaneous T-Cell Lymphoma (CTCL) Stages IA, IB & IIA
PI: Kim Soligenix

LYMNHL0124 Phase III SGX301 & Fluorescent Bulb-Light Irradiation in Treatment of Cutaneous T-Cell Lymphoma
PI: Kim Soligenix

LYMNHL0142 Phase II MK-3475 (Pembrolizumab) & Interferon Gamma 1-b +/- Immunotherapy in Previously Treated MF/SS
PI: Kim Citrin

1st priority

LYMNHL0136 Phase I Duvelisib in Combo w/ Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas
PI: Kim Memorial Sloan Kettering

2nd priority

LYMNHL0138 Phase 1/2A Cedulatinib (PRT062070) in Relapsed/Refractory CLL or SLL B-Cell or T-Cell NHL
PI: Kim Portola Pharmaceuticals

3rd priority

Failed 1 Therapy

Failed 2 Therapies

Failed 3 Therapies

LYMNHL0145 Phase III Topical Naloxone Hydrochloride Lotion 0.5% in MF or SS Forms of Cutaneous T-Cell Lymphoma
PI: Kim Soligenix

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu